Physician profile
David Buttross
NPI 1083615421
$4,201.30
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $734 · 2021: $1,012 · 2022: $1,077 · 2023: $571 · 2024: $19.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,122.50 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $651.09 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $597.76 | 2019-2023 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $421.04 | 2019-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $298.73 | 2019-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $281.83 | 2019-2022 | |
| Allergan, INC. | $243.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.31 | 2019-2023 | Trintellix |
| Indivior INC. | $78.50 | 2022-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.97 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $65.44 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $49.54 | 2019 | |
| Vanda Pharmaceuticals INC. | $48.94 | 2019-2021 | |
| Eisai INC. | $40.42 | 2020-2021 | |
| Tris Pharma INC | $34.70 | 2022-2023 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.61 | 2023 | Austedo Xr |
| Lundbeck LLC | $16.95 | 2022 | |
| Corium, LLC | $14.32 | 2023 | Azstarys |
| Shire North American Group INC | $11.84 | 2019 | |
| Neuronetics, INC. | $9.92 | 2019 | |
| Owp Pharmaceuticals, INC. | $4.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buttross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.